Generic Name and Formulations:
Lidocaine HCl (as monohydrate) 0.5mg/device; pwd for intradermal inj.
Indications for ZINGO:
To provide local analgesia prior to venipuncture in adults and children or peripheral IV cannulation in children.
Adults and Children:
<3yrs: not established. ≥3yrs: Use only on intact skin. Apply one 0.5mg dose to the planned procedure site 1–3 mins before needle insertion; may repeat once at new site after initial attempt failed. Multiple administrations to same site: not recommended.
Avoid eyes, body orifices, mucous membranes or areas with a compromised skin barrier. Severe hepatic disease or pseudocholinesterase deficiency. Bleeding tendencies or platelet disorders: higher risk of superficial dermal bleeding. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Local anesthetic (amide-type).
Additive effects with other local anesthetics.
Application-site reactions (eg, erythema, petechiae, edema, pruritus), systemic reactions (eg, nausea, vomiting), dizziness.
Single-use device (disposable, needle-free)—12
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Light Therapy May Prevent Depression During Hospitalization Post-Transplant in Multiple Myeloma
- Re-treatment With Checkpoint Inhibitors in Some Patients with NSCLC May Be Feasible
- TNFi Not Linked to Increased Risk for Cancer Recurrence in Rheumatoid Arthritis
- IL-23 Drives Castration-Resistant Prostate Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer